PURE EP™ Simulator Gets a U.S. Patent

On June 06, 2019, BioSig Technologies, Inc., a Westport, Conn.-based company that develops a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the U.S. Patent & Trademark Office allowed a U.S. patent application covering its electrophysiology simulator. The patent application number 15/103,278 entitled, "Systems and Methods For Evaluation of Electrophysiology Systems" was filed on June 9, 2016.

The BioSig Tech PURE EP System Aims for Arrhythmia Market

After nearly a decade of research and development, BioSig Tech could be poised to break into the nearly $5 billion global electrophysiology market.

In the spring of 2018, the West Los Angeles-based medical device company has filed for federal approval for a medical device that can help doctors target the cells that cause arrhythmias, or irregular heartbeats, which increase the risks of cardiac problems and stroke.

This biomedical device, called PURE EP, aims to cut through the background noise of the operating room and its equipment in order to allow doctors to pinpoint parts of the heart that cause atrial fibrillation and ventricular tachycardia.